Skip to main content
NCBI home page
Thorax logoLink to Thorax
. 2000 Feb;55(2):159–166. doi: 10.1136/thorax.55.2.159

Pleuropulmonary manifestations of systemic lupus erythematosus

M Keane 1, J Lynch 1
PMCID: PMC1745678  PMID: 10639536

Full Text

The Full Text of this article is available as a PDF (1.7 MB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abramson S. B., Dobro J., Eberle M. A., Benton M., Reibman J., Epstein H., Rapoport D. M., Belmont H. M., Goldring R. M. Acute reversible hypoxemia in systemic lupus erythematosus. Ann Intern Med. 1991 Jun 1;114(11):941–947. doi: 10.7326/0003-4819-114-11-941. [DOI] [PubMed] [Google Scholar]
  2. Abu-Shakra M., Gladman D. D., Urowitz M. B., Farewell V. Anticardiolipin antibodies in systemic lupus erythematosus: clinical and laboratory correlations. Am J Med. 1995 Dec;99(6):624–628. doi: 10.1016/s0002-9343(99)80249-6. [DOI] [PubMed] [Google Scholar]
  3. Adachi M., Watanabe-Fukunaga R., Nagata S. Aberrant transcription caused by the insertion of an early transposable element in an intron of the Fas antigen gene of lpr mice. Proc Natl Acad Sci U S A. 1993 Mar 1;90(5):1756–1760. doi: 10.1073/pnas.90.5.1756. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Andonopoulos A. P., Constantopoulos S. H., Galanopoulou V., Drosos A. A., Acritidis N. C., Moutsopoulos H. M. Pulmonary function of nonsmoking patients with systemic lupus erythematosus. Chest. 1988 Aug;94(2):312–315. doi: 10.1378/chest.94.2.312. [DOI] [PubMed] [Google Scholar]
  5. Argenbright L. W., Barton R. W. Interactions of leukocyte integrins with intercellular adhesion molecule 1 in the production of inflammatory vascular injury in vivo. The Shwartzman reaction revisited. J Clin Invest. 1992 Jan;89(1):259–272. doi: 10.1172/JCI115570. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Asherson R. A., Hackett D., Gharavi A. E., Harris E. N., Kennedy H. G., Hughes G. R. Pulmonary hypertension in systemic lupus erythematosus: a report of three cases. J Rheumatol. 1986 Apr;13(2):416–420. [PubMed] [Google Scholar]
  7. Asherson R. A., Oakley C. M. Pulmonary hypertension and systemic lupus erythematosus. J Rheumatol. 1986 Feb;13(1):1–5. [PubMed] [Google Scholar]
  8. Belmont H. M., Buyon J., Giorno R., Abramson S. Up-regulation of endothelial cell adhesion molecules characterizes disease activity in systemic lupus erythematosus. The Shwartzman phenomenon revisited. Arthritis Rheum. 1994 Mar;37(3):376–383. doi: 10.1002/art.1780370311. [DOI] [PubMed] [Google Scholar]
  9. Belmont H. M., Hopkins P., Edelson H. S., Kaplan H. B., Ludewig R., Weissmann G., Abramson S. Complement activation during systemic lupus erythematosus. C3a and C5a anaphylatoxins circulate during exacerbations of disease. Arthritis Rheum. 1986 Sep;29(9):1085–1089. doi: 10.1002/art.1780290905. [DOI] [PubMed] [Google Scholar]
  10. Beutler B., Bazzoni F. TNF, apoptosis and autoimmunity: a common thread? Blood Cells Mol Dis. 1998 Jun;24(2):216–230. doi: 10.1006/bcmd.1998.0187. [DOI] [PubMed] [Google Scholar]
  11. Bullard D. C., King P. D., Hicks M. J., Dupont B., Beaudet A. L., Elkon K. B. Intercellular adhesion molecule-1 deficiency protects MRL/MpJ-Fas(lpr) mice from early lethality. J Immunol. 1997 Aug 15;159(4):2058–2067. [PubMed] [Google Scholar]
  12. Buyon J. P., Tamerius J., Belmont H. M., Abramson S. B. Assessment of disease activity and impending flare in patients with systemic lupus erythematosus. Comparison of the use of complement split products and conventional measurements of complement. Arthritis Rheum. 1992 Sep;35(9):1028–1037. doi: 10.1002/art.1780350907. [DOI] [PubMed] [Google Scholar]
  13. Buyon J. P., Tamerius J., Ordorica S., Young B., Abramson S. B. Activation of the alternative complement pathway accompanies disease flares in systemic lupus erythematosus during pregnancy. Arthritis Rheum. 1992 Jan;35(1):55–61. doi: 10.1002/art.1780350109. [DOI] [PubMed] [Google Scholar]
  14. Cervera R., Khamashta M. A., Font J., Sebastiani G. D., Gil A., Lavilla P., Doménech I., Aydintug A. O., Jedryka-Góral A., de Ramón E. Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1,000 patients. The European Working Party on Systemic Lupus Erythematosus. Medicine (Baltimore) 1993 Mar;72(2):113–124. [PubMed] [Google Scholar]
  15. Conrad B., Weissmahr R. N., Böni J., Arcari R., Schüpbach J., Mach B. A human endogenous retroviral superantigen as candidate autoimmune gene in type I diabetes. Cell. 1997 Jul 25;90(2):303–313. doi: 10.1016/s0092-8674(00)80338-4. [DOI] [PubMed] [Google Scholar]
  16. Cush J. J., Goldings E. A. Drug-induced lupus: clinical spectrum and pathogenesis. Am J Med Sci. 1985 Jul;290(1):36–45. doi: 10.1097/00000441-198507000-00007. [DOI] [PubMed] [Google Scholar]
  17. Devinsky O., Petito C. K., Alonso D. R. Clinical and neuropathological findings in systemic lupus erythematosus: the role of vasculitis, heart emboli, and thrombotic thrombocytopenic purpura. Ann Neurol. 1988 Apr;23(4):380–384. doi: 10.1002/ana.410230411. [DOI] [PubMed] [Google Scholar]
  18. Dziarski R. Autoimmunity: polyclonal activation or antigen induction? Immunol Today. 1988 Nov;9(11):340–342. doi: 10.1016/0167-5699(88)91333-3. [DOI] [PubMed] [Google Scholar]
  19. Ellis S. G., Verity M. A. Central nervous system involvement in systemic lupus erythematosus: a review of neuropathologic findings in 57 cases, 1955--1977. Semin Arthritis Rheum. 1979 Feb;8(3):212–221. doi: 10.1016/s0049-0172(79)80009-8. [DOI] [PubMed] [Google Scholar]
  20. Erickson R. W., Franklin W. A., Emlen W. Treatment of hemorrhagic lupus pneumonitis with plasmapheresis. Semin Arthritis Rheum. 1994 Oct;24(2):114–123. doi: 10.1016/s0049-0172(05)80005-8. [DOI] [PubMed] [Google Scholar]
  21. Estes D., Christian C. L. The natural history of systemic lupus erythematosus by prospective analysis. Medicine (Baltimore) 1971 Mar;50(2):85–95. doi: 10.1097/00005792-197103000-00001. [DOI] [PubMed] [Google Scholar]
  22. Falk R. J., Dalmasso A. P., Kim Y., Lam S., Michael A. Radioimmunoassay of the attack complex of complement in serum from patients with systemic lupus erythematosus. N Engl J Med. 1985 Jun 20;312(25):1594–1599. doi: 10.1056/NEJM198506203122502. [DOI] [PubMed] [Google Scholar]
  23. Fauci A. S., Haynes B., Katz P. The spectrum of vasculitis: clinical, pathologic, immunologic and therapeutic considerations. Ann Intern Med. 1978 Nov;89(5 Pt 1):660–676. doi: 10.7326/0003-4819-89-5-660. [DOI] [PubMed] [Google Scholar]
  24. Fenlon H. M., Doran M., Sant S. M., Breatnach E. High-resolution chest CT in systemic lupus erythematosus. AJR Am J Roentgenol. 1996 Feb;166(2):301–307. doi: 10.2214/ajr.166.2.8553934. [DOI] [PubMed] [Google Scholar]
  25. Fishback N., Koss M. N. Pulmonary involvement in systemic lupus erythematosus. Curr Opin Pulm Med. 1995 Sep;1(5):368–375. [PubMed] [Google Scholar]
  26. Fletcher M. P., Seligmann B. E., Gallin J. I. Correlation of human neutrophil secretion, chemoattractant receptor mobilization, and enhanced functional capacity. J Immunol. 1982 Feb;128(2):941–948. [PubMed] [Google Scholar]
  27. Gamble D. R. The epidemiology of insulin dependent diabetes with particular reference to the relationship of virus infection to its etiology. Epidemiol Rev. 1980;2:49–70. doi: 10.1093/oxfordjournals.epirev.a036226. [DOI] [PubMed] [Google Scholar]
  28. Gammon R. B., Bridges T. A., al-Nezir H., Alexander C. B., Kennedy J. I., Jr Bronchiolitis obliterans organizing pneumonia associated with systemic lupus erythematosus. Chest. 1992 Oct;102(4):1171–1174. doi: 10.1378/chest.102.4.1171. [DOI] [PubMed] [Google Scholar]
  29. Ginzler E., Diamond H., Kaplan D., Weiner M., Schlesinger M., Seleznick M. Computer analysis of factors influencing frequency of infection in systemic lupus erythematosus. Arthritis Rheum. 1978 Jan-Feb;21(1):37–44. doi: 10.1002/art.1780210107. [DOI] [PubMed] [Google Scholar]
  30. Godeau B., Cormier C., Menkes C. J. Bronchiolitis obliterans in systemic lupus erythematosus: beneficial effect of intravenous cyclophosphamide. Ann Rheum Dis. 1991 Dec;50(12):956–958. doi: 10.1136/ard.50.12.956. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Goldhaber S. Z. Pulmonary embolism. N Engl J Med. 1998 Jul 9;339(2):93–104. doi: 10.1056/NEJM199807093390207. [DOI] [PubMed] [Google Scholar]
  32. Groen H., ter Borg E. J., Postma D. S., Wouda A. A., van der Mark T. W., Kallenberg C. G. Pulmonary function in systemic lupus erythematosus is related to distinct clinical, serologic, and nailfold capillary patterns. Am J Med. 1992 Dec;93(6):619–627. doi: 10.1016/0002-9343(92)90194-g. [DOI] [PubMed] [Google Scholar]
  33. Guerry-Force M. L., Müller N. L., Wright J. L., Wiggs B., Coppin C., Pare P. D., Hogg J. C. A comparison of bronchiolitis obliterans with organizing pneumonia, usual interstitial pneumonia, and small airways disease. Am Rev Respir Dis. 1987 Mar;135(3):705–712. doi: 10.1164/arrd.1987.135.3.705. [DOI] [PubMed] [Google Scholar]
  34. Hammad A., Tsukada Y., Torre N. Cerebral occlusive vasculopathy in systemic lupus erythematosus and speculation on the part played by complement. Ann Rheum Dis. 1992 Apr;51(4):550–552. doi: 10.1136/ard.51.4.550. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Haupt H. M., Moore G. W., Hutchins G. M. The lung in systemic lupus erythematosus. Analysis of the pathologic changes in 120 patients. Am J Med. 1981 Nov;71(5):791–798. doi: 10.1016/0002-9343(81)90366-1. [DOI] [PubMed] [Google Scholar]
  36. Hedgpeth M. T., Boulware D. W. Interstitial pneumonitis in antinuclear antibody-negative systemic lupus erythematosus: a new clinical manifestation and possible association with anti-Ro (SS-A) antibodies. Arthritis Rheum. 1988 Apr;31(4):545–548. doi: 10.1002/art.1780310412. [DOI] [PubMed] [Google Scholar]
  37. Hopkins P., Belmont H. M., Buyon J., Philips M., Weissmann G., Abramson S. B. Increased levels of plasma anaphylatoxins in systemic lupus erythematosus predict flares of the disease and may elicit vascular injury in lupus cerebritis. Arthritis Rheum. 1988 May;31(5):632–641. doi: 10.1002/art.1780310508. [DOI] [PubMed] [Google Scholar]
  38. Johnson R. T., Richardson E. P. The neurological manifestations of systemic lupus erythematosus. Medicine (Baltimore) 1968 Jul;47(4):337–369. doi: 10.1097/00005792-196807000-00002. [DOI] [PubMed] [Google Scholar]
  39. Jones S. M., Mathew C. M., Dixey J., Lovell C. R., McHugh N. J. VCAM-1 expression on endothelium in lesions from cutaneous lupus erythematosus is increased compared with systemic and localized scleroderma. Br J Dermatol. 1996 Nov;135(5):678–686. [PubMed] [Google Scholar]
  40. Kaine J. L. Refractory massive pleural effusion in systemic lupus erythematosus treated with talc poudrage. Ann Rheum Dis. 1985 Jan;44(1):61–64. doi: 10.1136/ard.44.1.61. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Katzenstein A. L., Myers J. L., Prophet W. D., Corley L. S., 3rd, Shin M. S. Bronchiolitis obliterans and usual interstitial pneumonia. A comparative clinicopathologic study. Am J Surg Pathol. 1986 Jun;10(6):373–381. doi: 10.1097/00000478-198606000-00002. [DOI] [PubMed] [Google Scholar]
  42. Kawaguchi Y., Hara M., Harigai M., Sakurada M., Nakamura H., Kashiwazaki S. Corticosteroid pulse therapy in a patient with SLE and pulmonary hypertension. Clin Exp Rheumatol. 1998 Jul-Aug;16(4):510–510. [PubMed] [Google Scholar]
  43. Keane M. P., Van De Ven C. J., Lynch J. P., 3rd, McCune W. J. Systemic lupus during pregnancy with refractory alveolar haemorrhage: recovery following termination of pregnancy. Lupus. 1997;6(9):730–733. doi: 10.1177/096120339700600909. [DOI] [PubMed] [Google Scholar]
  44. Kerr L. D., Adelsberg B. R., Schulman P., Spiera H. Factor B activation products in patients with systemic lupus erythematosus. A marker of severe disease activity. Arthritis Rheum. 1989 Nov;32(11):1406–1413. doi: 10.1002/anr.1780321109. [DOI] [PubMed] [Google Scholar]
  45. Khamashta M. A., Cuadrado M. J., Mujic F., Taub N. A., Hunt B. J., Hughes G. R. The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med. 1995 Apr 13;332(15):993–997. doi: 10.1056/NEJM199504133321504. [DOI] [PubMed] [Google Scholar]
  46. Kinney W. W., Angelillo V. A. Bronchiolitis in systemic lupus erythematosus. Chest. 1982 Nov;82(5):646–649. doi: 10.1378/chest.82.5.646. [DOI] [PubMed] [Google Scholar]
  47. Klinman D. M. Polyclonal B cell activation in lupus-prone mice precedes and predicts the development of autoimmune disease. J Clin Invest. 1990 Oct;86(4):1249–1254. doi: 10.1172/JCI114831. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Klinman D. M., Shirai A., Ishigatsubo Y. Polyclonal B cell activation and B cell cross-reactivity during autoantibody production in systemic lupus erythematosus. Adv Exp Med Biol. 1994;347:115–123. doi: 10.1007/978-1-4615-2427-4_12. [DOI] [PubMed] [Google Scholar]
  49. Krnic-Barrie S., O'Connor C. R., Looney S. W., Pierangeli S. S., Harris E. N. A retrospective review of 61 patients with antiphospholipid syndrome. Analysis of factors influencing recurrent thrombosis. Arch Intern Med. 1997 Oct 13;157(18):2101–2108. [PubMed] [Google Scholar]
  50. Kurtzke J. F. Epidemiologic evidence for multiple sclerosis as an infection. Clin Microbiol Rev. 1993 Oct;6(4):382–427. doi: 10.1128/cmr.6.4.382. [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. Liu M. F., Lee J. H., Weng T. H., Lee Y. Y. Clinical experience of 13 cases with severe pulmonary hemorrhage in systemic lupus erythematosus with active nephritis. Scand J Rheumatol. 1998;27(4):291–295. doi: 10.1080/030097498442406. [DOI] [PubMed] [Google Scholar]
  52. Mana F., Mets T., Vincken W., Sennesael J., Vanwaeyenbergh J., Goossens A. The association of bronchiolitis obliterans organizing pneumonia, systemic lupus erythematosus, and Hunner's cystitis. Chest. 1993 Aug;104(2):642–644. doi: 10.1378/chest.104.2.642. [DOI] [PubMed] [Google Scholar]
  53. Martinez-Taboada V. M., Blanco R., Armona J., Fernandez-Sueiro J. L., Rodriguez-Valverde V. Acute reversible hypoxemia in systemic lupus erythematosus: a new syndrome or an index of disease activity? Lupus. 1995 Aug;4(4):259–262. doi: 10.1177/096120339500400405. [DOI] [PubMed] [Google Scholar]
  54. Matthay R. A., Schwarz M. I., Petty T. L., Stanford R. E., Gupta R. C., Sahn S. A., Steigerwald J. C. Pulmonary manifestations of systemic lupus erythematosus: review of twelve cases of acute lupus pneumonitis. Medicine (Baltimore) 1975 Sep;54(5):397–409. doi: 10.1097/00005792-197509000-00003. [DOI] [PubMed] [Google Scholar]
  55. Merino R., Iwamoto M., Fossati L., Izui S. Polyclonal B cell activation arises from different mechanisms in lupus-prone (NZB x NZW)F1 and MRL/MpJ-lpr/lpr mice. J Immunol. 1993 Dec 1;151(11):6509–6516. [PubMed] [Google Scholar]
  56. Murin S., Wiedemann H. P., Matthay R. A. Pulmonary manifestations of systemic lupus erythematosus. Clin Chest Med. 1998 Dec;19(4):641-65, viii. doi: 10.1016/s0272-5231(05)70108-8. [DOI] [PubMed] [Google Scholar]
  57. Muñoz-Rodríguez F. J., Font J., Badia J. R., Miret C., Barberà J. A., Cervera R., Ingelmo M. Shrinking lungs syndrome in systemic lupus erythematosus: improvement with inhaled beta-agonist therapy. Lupus. 1997;6(4):412–414. doi: 10.1177/096120339700600413. [DOI] [PubMed] [Google Scholar]
  58. Myers J. L., Katzenstein A. A. Microangiitis in lupus-induced pulmonary hemorrhage. Am J Clin Pathol. 1986 May;85(5):552–556. doi: 10.1093/ajcp/85.5.552. [DOI] [PubMed] [Google Scholar]
  59. Nadorra R. L., Landing B. H. Pulmonary lesions in childhood onset systemic lupus erythematosus: analysis of 26 cases, and summary of literature. Pediatr Pathol. 1987;7(1):1–18. doi: 10.1080/15513818709177110. [DOI] [PubMed] [Google Scholar]
  60. Naylor B. Cytological aspects of pleural, peritoneal and pericardial fluids from patients with systemic lupus erythematosus. Cytopathology. 1992;3(1):1–8. doi: 10.1111/j.1365-2303.1992.tb00014.x. [DOI] [PubMed] [Google Scholar]
  61. Nyberg F., Acevedo F., Stephansson E. Different patterns of soluble adhesion molecules in systemic and cutaneous lupus erythematosus. Exp Dermatol. 1997 Oct;6(5):230–235. doi: 10.1111/j.1600-0625.1997.tb00167.x. [DOI] [PubMed] [Google Scholar]
  62. Oldstone M. B. Molecular mimicry and immune-mediated diseases. FASEB J. 1998 Oct;12(13):1255–1265. doi: 10.1096/fasebj.12.13.1255. [DOI] [PMC free article] [PubMed] [Google Scholar]
  63. Orens J. B., Martinez F. J., Lynch J. P., 3rd Pleuropulmonary manifestations of systemic lupus erythematosus. Rheum Dis Clin North Am. 1994 Feb;20(1):159–193. [PubMed] [Google Scholar]
  64. Otsuka F., Amano T., Hashimoto N., Takahashi M., Hayakawa N., Makino H., Ota Z., Ogura T. Bronchiolitis obliterans organizing pneumonia associated with systemic lupus erythematosus with antiphospholipid antibody. Intern Med. 1996 Apr;35(4):341–344. doi: 10.2169/internalmedicine.35.341. [DOI] [PubMed] [Google Scholar]
  65. Pandya M. R., Agus B., Grady R. F. Letter: In vivo LE phenomenon in pleural fluid. Arthritis Rheum. 1976 Sep-Oct;19(5):962–963. doi: 10.1002/art.1780190526. [DOI] [PubMed] [Google Scholar]
  66. Panitch H. S. Influence of infection on exacerbations of multiple sclerosis. Ann Neurol. 1994;36 (Suppl):S25–S28. doi: 10.1002/ana.410360709. [DOI] [PMC free article] [PubMed] [Google Scholar]
  67. Radic M. Z., Weigert M. Genetic and structural evidence for antigen selection of anti-DNA antibodies. Annu Rev Immunol. 1994;12:487–520. doi: 10.1146/annurev.iy.12.040194.002415. [DOI] [PubMed] [Google Scholar]
  68. Riska H., Fyhrquist F., Selander R. K., Hellström P. E. Systemic lupus erythematosus and DNA antibodies in pleural effusions. Scand J Rheumatol. 1978;7(3):159–160. doi: 10.3109/03009747809095646. [DOI] [PubMed] [Google Scholar]
  69. Rosove M. H., Brewer P. M. Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients. Ann Intern Med. 1992 Aug 15;117(4):303–308. doi: 10.7326/0003-4819-117-4-303. [DOI] [PubMed] [Google Scholar]
  70. Rozzo S. J., Drake C. G., Chiang B. L., Gershwin M. E., Kotzin B. L. Evidence for polyclonal T cell activation in murine models of systemic lupus erythematosus. J Immunol. 1994 Aug 1;153(3):1340–1351. [PubMed] [Google Scholar]
  71. Rudd R. M., Haslam P. L., Turner-Warwick M. Cryptogenic fibrosing alveolitis. Relationships of pulmonary physiology and bronchoalveolar lavage to response to treatment and prognosis. Am Rev Respir Dis. 1981 Jul;124(1):1–8. doi: 10.1164/arrd.1981.124.1.1. [DOI] [PubMed] [Google Scholar]
  72. Röcken M., Urban J. F., Shevach E. M. Infection breaks T-cell tolerance. Nature. 1992 Sep 3;359(6390):79–82. doi: 10.1038/359079a0. [DOI] [PubMed] [Google Scholar]
  73. Sahn S. A. The pathophysiology of pleural effusions. Annu Rev Med. 1990;41:7–13. doi: 10.1146/annurev.me.41.020190.000255. [DOI] [PubMed] [Google Scholar]
  74. Schulman S., Svenungsson E., Granqvist S. Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Duration of Anticoagulation Study Group. Am J Med. 1998 Apr;104(4):332–338. doi: 10.1016/s0002-9343(98)00060-6. [DOI] [PubMed] [Google Scholar]
  75. Schwab E. P., Schumacher H. R., Jr, Freundlich B., Callegari P. E. Pulmonary alveolar hemorrhage in systemic lupus erythematosus. Semin Arthritis Rheum. 1993 Aug;23(1):8–15. doi: 10.1016/s0049-0172(05)80022-8. [DOI] [PubMed] [Google Scholar]
  76. Singh R. R., Hahn B. H., Tsao B. P., Ebling F. M. Evidence for multiple mechanisms of polyclonal T cell activation in murine lupus. J Clin Invest. 1998 Nov 15;102(10):1841–1849. doi: 10.1172/JCI3872. [DOI] [PMC free article] [PubMed] [Google Scholar]
  77. Sliwinski A. J., Zvaifler N. J. Decreased synthesis of the third component of complement (C3) in hypocomplementemic systemic lupus erythematosus. Clin Exp Immunol. 1972 May;11(1):21–29. [PMC free article] [PubMed] [Google Scholar]
  78. Soos J. M., Schiffenbauer J., Torres B. A., Johnson H. M. Superantigens as virulence factors in autoimmunity and immunodeficiency diseases. Med Hypotheses. 1997 Mar;48(3):253–259. doi: 10.1016/s0306-9877(97)90315-7. [DOI] [PubMed] [Google Scholar]
  79. Tam L. S., Li E. K. Successful treatment with immunosuppression, anticoagulation and vasodilator therapy of pulmonary hypertension in SLE associated with secondary antiphospholipid syndrome. Lupus. 1998;7(7):495–497. doi: 10.1191/096120398678920442. [DOI] [PubMed] [Google Scholar]
  80. Thompson P. J., Dhillon D. P., Ledingham J., Turner-Warwick M. Shrinking lungs, diaphragmatic dysfunction, and systemic lupus erythematosus. Am Rev Respir Dis. 1985 Oct;132(4):926–928. doi: 10.1164/arrd.1985.132.4.926. [DOI] [PubMed] [Google Scholar]
  81. Turner-Stokes L., Haslam P., Jones M., Dudeney C., Le Page S., Isenberg D. Autoantibody and idiotype profile of lung involvement in autoimmune rheumatic disease. Ann Rheum Dis. 1990 Mar;49(3):160–162. doi: 10.1136/ard.49.3.160. [DOI] [PMC free article] [PubMed] [Google Scholar]
  82. Van Veen S., Peeters A. J., Sterk P. J., Breedveld F. C. The "shrinking lung syndrome" in SLE, treatment with theophylline. Clin Rheumatol. 1993 Dec;12(4):462–465. doi: 10.1007/BF02231771. [DOI] [PubMed] [Google Scholar]
  83. Walz-Leblanc B. A., Urowitz M. B., Gladman D. D., Hanly P. J. The "shrinking lungs syndrome" in systemic lupus erythematosus--improvement with corticosteroid therapy. J Rheumatol. 1992 Dec;19(12):1970–1972. [PubMed] [Google Scholar]
  84. Watanabe-Fukunaga R., Brannan C. I., Copeland N. G., Jenkins N. A., Nagata S. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature. 1992 Mar 26;356(6367):314–317. doi: 10.1038/356314a0. [DOI] [PubMed] [Google Scholar]
  85. Weinrib L., Sharma O. P., Quismorio F. P., Jr A long-term study of interstitial lung disease in systemic lupus erythematosus. Semin Arthritis Rheum. 1990 Aug;20(1):48–56. doi: 10.1016/0049-0172(90)90094-v. [DOI] [PubMed] [Google Scholar]
  86. Wells A. U., du Bois R. M. Bronchiolitis in association with connective tissue disorders. Clin Chest Med. 1993 Dec;14(4):655–666. [PubMed] [Google Scholar]
  87. Wiedemann H. P., Matthay R. A. Pulmonary manifestations of the collagen vascular diseases. Clin Chest Med. 1989 Dec;10(4):677–722. [PubMed] [Google Scholar]
  88. Yung R. L., Richardson B. C. Drug-induced lupus. Rheum Dis Clin North Am. 1994 Feb;20(1):61–86. [PubMed] [Google Scholar]
  89. Zamora M. R., Warner M. L., Tuder R., Schwarz M. I. Diffuse alveolar hemorrhage and systemic lupus erythematosus. Clinical presentation, histology, survival, and outcome. Medicine (Baltimore) 1997 May;76(3):192–202. doi: 10.1097/00005792-199705000-00005. [DOI] [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES